XM không cung cấp dịch vụ cho cư dân của Mỹ.
R
R

Roche


Tin tức

Brainy efforts underway, but still some way to go for neuro drug developers

LIVE MARKETS-Brainy efforts underway, but still some way to go for neuro drug developers Main U.S. indexes sharply higher; Nasdaq, Dow up 1.3% Cons Disc leads S&P sector gainers; Utilities sole loser Euro STOXX 600 index up 1.3% Dollar rises; gold edges up; crude, up >1%, bitcoin up 0.4% U.S. 10-Year Treasury yield edges up to ~4.33% Welcome to the home for real-time coverage of markets brought to you by Reuters reporters.
A
B
R
U
U

Regeneron shares drop as higher-dose Eylea drug misses sales estimates

UPDATE 1-Regeneron shares drop as higher-dose Eylea drug misses sales estimates Rewrites throughout to add details on higher dose version of Eylea By Christy Santhosh Oct 31 (Reuters) - U.S. drugmaker Regeneron Pharmaceuticals REGN.O o n Thursday reported weaker-than-expected quarterly sales of the higher dose version of its blockbuster eye disease drug Eylea, sending its shares down 9%.
B
R
R
S

Regeneron beats results estimates on demand for eczema treatment, eye drug

Regeneron beats results estimates on demand for eczema treatment, eye drug Oct 31 (Reuters) - U.S. drugmaker Regeneron Pharmaceuticals REGN.O beat Wall Street estimates for third-quarter profit and revenue on Thursday, driven by strong demand for its eczema treatment Dupixent and blockbuster eye disease drug Eylea. Regeneron has been looking to upgrade patients who use Eylea to a high-dose version, as the drug that has long been its cash cow faces the threat of biosimilar products and stiff comp
B
R
R
S

Roche Presents New Data On Elecsys Amyloid Plasma Panel And Elecsys Ptau181

BRIEF-Roche Presents New Data On Elecsys Amyloid Plasma Panel And Elecsys Ptau181 Oct 31 (Reuters) - ROCHE HOLDING AG ROG.S : PRESENTS NEW DATA AT CTAD, DEMONSTRATING ITS GROWING MOMENTUM IN DIAGNOSTICS FOR ALZHEIMER'S DISEASE NEW DATA HIGHLIGHT POTENTIAL OF ROCHE ELECSYS® AMYLOID PLASMA PANEL AND ELECSYS PTAU181 FOR RULING OUT ALZHEIMER'S DISEASE
R

New England Journal Of Medicine Publishes Results For Roche's Itovebi, Showing More Than Doubling Of Progression-Free Survival In Certain Type Of Hr-Positive Advanced Breast Cancer

BRIEF-New England Journal Of Medicine Publishes Results For Roche's Itovebi, Showing More Than Doubling Of Progression-Free Survival In Certain Type Of Hr-Positive Advanced Breast Cancer Oct 31 (Reuters) - Roche Holding AG ROG.S : NEW ENGLAND JOURNAL OF MEDICINE PUBLISHES LANDMARK PHASE III RESULTS FOR ROCHE’S ITOVEBI, SHOWING MORE THAN DOUBLING OF PROGRESSION-FREE SURVIVAL IN CERTAIN TYPE OF HR-POSITIVE ADVANCED BREAST CANCER U.S.
R

Nikkei closes at 2-week peak as tech shares track Nasdaq higher

Nikkei closes at 2-week peak as tech shares track Nasdaq higher Updates at 0600 GMT TOKYO, Oct 30 (Reuters) - Japan's Nikkei share average rose to a two-week closing high on Wednesday, as technology stocks tracked the Nasdaq's record finish overnight. The Nikkei .N225 climbed 0.96% to 39,277.39, its highest close since Oct. 15 in its third straight session of gains.
G
R
U
J
U
U

Japan's Nikkei hits two-week high as tech shares track Nasdaq's record high

Japan's Nikkei hits two-week high as tech shares track Nasdaq's record high TOKYO, Oct 30 (Reuters) - Japan's Nikkei share average touched a two-week high on Wednesday, as technology stocks tracked Nasdaq's record closing high overnight. The Nikkei .N225 was up 1.25% at 39,390.49 by the midday break, its highest level since Oct. 15. The broader Topix .TOPX rose 1.13% to 2,712.26. "There were not any strong market-moving cues and the momentum is not strong," said Fumio Matsumoto, chief strategist
G
N
R
U
J
U
U

NIH Says Bovine H5N1 Virus Is Susceptible To Antiviral Xofluza & Zanamivir

BRIEF-NIH Says Bovine H5N1 Virus Is Susceptible To Antiviral Xofluza & Zanamivir Oct 28 (Reuters) - NIH: NIH: BOVINE H5N1 INFLUENZA FROM INFECTED WORKER TRANSMISSIBLE AND LETHAL IN ANIMAL MODELS NIH: STUDY SHOWED BOVINE H5N1 VIRUS IS SUSCEPTIBLE TO ANTIVIRAL XOFLUZA AND NEURAMINIDASE INHIBITOR ZANAMIVIR NIH: STUDY SHOWED BOVINE H5N1 VIRUS IS LESS S
G
R

Assa Abloy, Kering, L'Oréal

EUROPE RESEARCH ROUNDUP-Assa Abloy, Kering, L'Oréal Oct 24 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Assa Abloy, Kering and L'Oréal, on Thursday. HIGHLIGHTS * Assa Abloy ASSAb.ST : Deutsche Bank raises target price to SEK 305 from SEK 300 * Barratt Redrow Plc BTRW.L : Morgan Stanley cuts target price to 580p from 600p * Dowlais Group Plc DWL.L : Citigroup raises to neutral from sell * Kering PRTP.PA : JP Morgan cuts target
B
D
D
D
E
E
H
H
K
K
L
L
P
R
R
R
S
S
S
S
S
T
Z
A
A
A
A
A
E
S

Roche comes out against allowing takeover of drug manufacturer Catalent

UPDATE 5-Roche comes out against allowing takeover of drug manufacturer Catalent Adds comment from Novo Holdings in paragraph 13 Roche CEO: not good to limit competition in this space Roche says not itself, but others affected by Catalent deal Swiss drugmaker joins US peer Lilly in voicing opposition Eli Lilly and advocacy groups also voice concerns over the deal Novo Nordisk and Catalent defend the acquisition, citing ample competition By Ludwig Burger FRANKFURT, Oct 23 (Reuters) - The CEO of p
A
A
P
R

Europe struggles for direction, earnings mixed

LIVE MARKETS-Europe struggles for direction, earnings mixed STOXX 600 flat Deutsche Bank, L'Oreal fall after earnings Wall St futures lower Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com EUROPE STRUGGLES FOR DIRECTION, EARNINGS MIXED European equities are mixed on Wednesday, after several corporate reports, with markets remaining on edge as the U.S.
D
I
L
L
R
S
V
S
E
F
U
G

Roche CEO comes out against approving takeover of drug manufacturer Catalent

Roche CEO comes out against approving takeover of drug manufacturer Catalent FRANKFURT, Oct 23 (Reuters) - The CEO of Swiss pharmaceuticals giant Roche ROG.S said competition authorities should not allow the controlling shareholder of Novo Nordisk NOVOb.CO to acquiring contract drug manufacturer Catalent CTLT.N . "It's not a problem for us, but it could be a problem for other smaller players, if there is a restriction in how many (contract manufacturers) are available.
R

Europe before the bell: futures dip after raft of earnings

LIVE MARKETS-Europe before the bell: futures dip after raft of earnings Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com EUROPE BEFORE THE BELL: FUTURES DIP AFTER RAFT OF EARNINGS European stock futures are edging lower in early trade after a large number of corporate earnings, with markets also watching rising yields and preparing for the upcoming U.S.
D
I
L
P
R
V
E
F
U
G

Roche CEO says more people have mpox in Europe than has been reported

UPDATE 1-Roche CEO says more people have mpox in Europe than has been reported Adds production capacity detail, background on mpox spread By Ludwig Burger FRANKFURT, Oct 23 (Reuters) - The CEO of Roche ROG.S said he has been informed that more cases of mpox infection have occurred in Europe than previously reported and that the Swiss group could quickly offer 10 times more test kits than are currently in demand.
R

Roche seen rising after Q3 sales beat

BUZZ-Roche seen rising after Q3 sales beat ** Shares in Roche ROG.S are indicated up 1.1% in Julius Baer premarket trade after the Swiss drugmaker reports better-than-expected Q3 sales ** "Reported 3Q24 Group sales beats consensus and our expectations," Vontobel says ** Key growth drivers such as multiple sclerosis drug Ocrevus, haemophilia shot Hemlibra and recently launched eye drug Vabysmo continue to perform above expectations, the brokerage highlights ** Analysts at J.P.
R
J

Roche CEO says more mpox cases likely to be reported in Europe

Roche CEO says more mpox cases likely to be reported in Europe FRANKFURT, Oct 23 (Reuters) - The CEO of Roche ROG.S said more cases of mpox infection have likely occurred in Europe than previously reported and that the group could quickly offer 10 times more test kits than are currently in demand. "It seems like there are more mpox cases already in Europe, maybe not all of them are in the media yet," CEO Thomas Schinecker said in a media call after the Swiss drugs and diagnostics company reporte
R

Roche Q3 sales advance by forex-adj 9%, beating market view

UPDATE 1-Roche Q3 sales advance by forex-adj 9%, beating market view Adds details on drugs, full-year guidance By Ludwig Burger FRANKFURT, Oct 23 (Reuters) - Roche 's ROG.S third-quarter sales gained a currency-adjusted 9% , beating market expectations, on higher prescriptions of once-monthly haemophilia shot Hemlibra and recently launched eye drug Vabysmo.
R

Roche Q3 sales advance by forex-adj 9%, beating market view

Roche Q3 sales advance by forex-adj 9%, beating market view FRANKFURT, Oct 23 (Reuters) - Roche ROG.S on Wednesday said that third-quarter sales gained a currency-adjusted 9% to 15.14 billion Swiss francs ($17.46 billion). That surpassed an analysts' consensus estimate of 14.9 billion francs, based on LSEG data. ($1 = 0.8671 Swiss francs) Reporting
R

FDA approves Astellas' gastric cancer therapy

UPDATE 4-FDA approves Astellas' gastric cancer therapy Adds pricing and availability in paragraph 4 By Sriparna Roy Oct 18 (Reuters) - The U.S. Food and Drug Administration approved Astellas' 4503.T therapy to treat a type of gastric cancer, the health regulator's website showed on Friday. The therapy, branded as Vyloy, was approved to be used in combination with a type of chemotherapy for patients with a type of cancer which begins in the gastroesophageal junction, where the esophagus and stoma
A
R

Japan corporate earnings week ahead

DIARY-Japan corporate earnings week ahead Oct 18 (Reuters) - Diary of Japan (.N225) corporate earnings for the week ahead JAPAN EARNINGS Start Date Start Time(GMT) RIC Company Name Event Name 23-Oct-2024 06:15 6594.T Nidec Corp Q2 2025 Nidec Corp Earnings Release 24-Oct-2024 06:00 7751.T Canon Inc Q3 2024 Canon Inc Earnings Release 25-Oct-2024 08:00 4519.T Chugai Pharmaceutical Co Ltd Q3 2024 Chugai Pharmaceutical Co Ltd Earnings Release 25-Oct-2024 06:00 6954.T Fanuc Corp Q2 2025 Fanuc Corp Ear
R
J



Các điều kiện

Các tài sản phổ thông

Khước từ trách nhiệm: các tổ chức thuộc XM Group chỉ cung cấp dịch vụ khớp lệnh và truy cập Trang Giao dịch trực tuyến của chúng tôi, cho phép xem và/hoặc sử dụng nội dung có trên trang này hoặc thông qua trang này, mà hoàn toàn không có mục đích thay đổi hoặc mở rộng. Việc truy cập và sử dụng như trên luôn phụ thuộc vào: (i) Các Điều kiện và Điều khoản; (ii) Các Thông báo Rủi ro; và (iii) Khước từ trách nhiệm toàn bộ. Các nội dung như vậy sẽ chỉ được cung cấp dưới dạng thông tin chung. Đặc biệt, xin lưu ý rằng các thông tin trên Trang Giao dịch trực tuyến của chúng tôi không phải là sự xúi giục, mời chào để tham gia bất cứ giao dịch nào trên các thị trường tài chính. Giao dịch các thị trường tài chính có rủi ro cao đối với vốn đầu tư của bạn.

Tất cả các tài liệu trên Trang Giao dịch trực tuyến của chúng tôi chỉ nhằm các mục đích đào tạo/cung cấp thông tin và không bao gồm - và không được coi là bao gồm - các tư vấn tài chính, đầu tư, thuế, hoặc giao dịch, hoặc là một dữ liệu về giá giao dịch của chúng tôi, hoặc là một lời chào mời, hoặc là một sự xúi giục giao dịch các sản phẩm tài chính hoặc các chương trình khuyến mãi tài chính không tự nguyện.

Tất cả nội dung của bên thứ ba, cũng như nội dung của XM như các ý kiến, tin tức, nghiên cứu, phân tích, giá cả, các thông tin khác hoặc các đường dẫn đến trang web của các bên thứ ba có trên trang web này được cung cấp với dạng "nguyên trạng", là các bình luận chung về thị trường và không phải là các tư vấn đầu tư. Với việc các nội dung đều được xây dựng với mục đích nghiên cứu đầu tư, bạn cần lưu ý và hiểu rằng các nội dung này không nhằm mục đích và không được biên soạn để tuân thủ các yêu cầu pháp lý đối với việc quảng bá nghiên cứu đầu tư này và vì vậy, được coi như là một tài liệu tiếp thị. Hãy chắc chắn rằng bạn đã đọc và hiểu Thông báo về Nghiên cứu Đầu tư không độc lập và Cảnh báo Rủi ro tại đây liên quan đến các thông tin ở trên.

Cảnh báo rủi ro: Vốn của bạn bị rủi ro. Các sản phẩm có đòn bẩy có thể không phù hợp với tất cả mọi người. Hãy xem kỹ Thông báo rủi ro của chúng tôi.